Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study

Therapeutic Innovation and Regulatory Science

Volumn 47, Issue 1, 2013, Pages 95-100

  Zhang, Lijun ^a   Ko, Chia Wen ^a   Tang, Shenghui ^a   Sridhara, Rajeshwari ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

clinical trial; crossover; overall survival; progression free survival; survival post progression

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; OVERALL SURVIVAL; PARAMETERS; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; SIMULATION; SURVIVAL POST PROGRESSION;

EID: 84877343468     PISSN: 21684790     EISSN: 21649200     Source Type: Journal    
DOI: 10.1177/0092861512459180     Document Type: Article

References (8)

1. Pazdur R.Endpoints for assessing drug activity in clinical trials.Oncologist. 2008;13 (suppl 2): 19-21.
2. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics; 2007:.
3. Beckman M.More clinical cancer treatments judged by progression-free rather than overall survival.J Natl Cancer Inst. 2007;14:1068-1069.
4. Verma S,McLeod D,Batist G,Robidoux A,Martins IRS,Mackey JR.In the end what matters most? a review of clinical endpoints in advanced breast cancer.Oncologist. 2011;16:25-35.
5. Zhuang SH,Xiu L,Elsayed YA.Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.Cancer J. 2009;15 (5): 395-400.
6. Broglio KR,Berry DA.Detecting an overall survival benefit that is derived from progression-free survival.J Natl Cancer Inst. 2009;101:1642-1649.
7. Fleischer F,Gaschler-Markefski B,Bluhmki E.A statistical model for the dependence between progression-free survival and overall survival.Stat Med. 2009;28:2669-2686.
8. Korn EL,Freidlin B,Abrams JS.Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.J Clin Oncol. 2011;17:2439-2442.